FINWIRES · TerminalLIVE
FINWIRES

Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says

By

Travere Therapeutics (TVTX) shows a favorable setup on account of growth assets like Filspari, which is expected to draw "strong interest" as the first approved therapy for focal segmental glomerulosclerosis in the US, Wedbush Securities said in a note Monday.

The brokerage said Filspari patient start forms reached 993 in Q1, up 9% quarter-on-quarter, and are expected to increase to about 1,200 in Q2.

For Q2, Wedbush said it expects US Filspari revenue of $135 million, compared with consensus of $131 million, assuming $6 million for FSGS and $129 million for the IgA nephropathy indication.

Additionally, Wedbush increased its fiscal 2027 and beyond Filspari revenue trajectory on account of both higher net pricing and uptake in the FSGS segment, according to the note.

Wedbush Securities raised its price target to $61 from $55, and maintained its outperform rating on the stock.

Price: $55.61, Change: $+0.45, Percent Change: +0.83%

Related Articles

Wire

Pacgold Says Non-Executive Chair Resigns

Pacgold (ASX:PGO) said Caoilin Chestnutt has resigned as its non-executive chair, effective June 19, according to a Monday Australian bourse filing.Richard Hacker was appointed as Chestnutt's successor, per the filing.The company's shares fell 2% in recent trading on Monday.

ASX:PGO
Wire

Update: EQT Holdings Plans to Stop Offering Independent Superannuation Trusteeship, Shift Focus to Core Corporate Trustee Services; Shares Fall 13%

(Updates with the stock movement in the headline and last paragraph.)EQT Holdings (ASX:EQT) plans to stop offering independent superannuation trusteeship as part of a strategic decision to focus on its core corporate trustee services and trustee and wealth services businesses, according to a Monday filing with the Australian bourse.The decision follows a review that evaluated market dynamics, operating requirements, long-term growth opportunities, as well as shifting client needs as two of the company's major superannuation clients are considering a move to internalize trusteeship.If Equity Trustees Superannuation retires from its superannuation trustee appointments, EQT Holdings will be required to repay operational risk financial requirements loan facilities of AU$36 million, the company said.It added that the move is expected to result in a one-off non-cash impairment charge estimated at about AU$13 million in fiscal 2026 results, while total legal and advisory costs related to the review are expected to be about AU$6.3 million for the fiscal year.Additionally, the company also expects to incur about AU$2.2 million of net legal and advisory costs in the second half of the fiscal year for legal proceedings related to the Shield and First Guardian Master Funds.EQT Holdings said its Superannuation Trustee Services business accounted for 5% of the group's net profit before tax in the first half of fiscal 2026.The company's shares fell 13% in recent Monday trade.

ASX:EQT
Wire

NobleOak Life Reports 9% Embedded Value Growth; Achieves Fiscal 2026 In-Force Premium Guidance; Shares Up 3%

NobleOak Life (ASX:NOL) said it increased its embedded value by 9% year over year to AU$2.34 per share, or AU$217.7 million, as of the end of 2025, according to a Monday filing with the Australian bourse.Excluding a previously disclosed one-off Victorian stamp duty provision, annual embedded value growth would have been about 13%, reflecting profitable growth of in-force premiums and continued market share gains, the company said.It also reported AU$538 million of in-force premiums as of May 31, up 16% from a year earlier, marking the achievement of its fiscal 2026 guidance for growth of more than 15%, per the filing.The company's shares gained nearly 3% in recent Monday trade.

ASX:NOL